Clinical Trial

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

Name: Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia — clinical trial record (NCT07311746)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

The goal of this clinical research study is to learn if the combination of ruxolitinib with cladribine and venetoclax can help to control the disease in patients with R/R T-PLL.

Protocol Amendment History 1 change

critical Recruitment opened 2026-07-16

Trial Details

NCT Number	NCT07311746
Lead Sponsor	M.D. Anderson Cancer Center
Conditions	T-cell Prolymphocytic Leukemia, Refractory T-Cell Prolymphocytic Leukemia
Enrollment	36 participants
Start Date	2026-04-28
Primary Completion	2029-01-31 (estimated)
Study Completion	2031-01-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-12